Carmel Medical Center

Running trials

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Source

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Source

• Recruiting

  A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

  NCT07470879· Phase 2· Source

• Recruiting

  A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

  NCT07440225· Phase 2/3· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Source

• Active, not recruiting

  COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

  NCT07449936· Phase 3· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Source

• Recruiting

  A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  NCT07175285· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Phase 3· Source

• Recruiting

  Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

  NCT07064759· Phase 3· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Source

• Recruiting

  The Effect of Temporary Ovarian Suspension to the Abdominal Wall During Laparoscopic Endometriosis Surgery for Adhesion Prevention -A Comparative and Prospective Study

  NCT07087756· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

  NCT06680817· Source

• Enrolling by invitation

  A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

  NCT06788509· Phase 1· Source

• Recruiting

  A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

  NCT06768489· Phase 1· Source

• Active, not recruiting

  Nipocalimab in Moderate to Severe Sjogren's Disease

  NCT06741969· Phase 3· Source

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

  NCT06683742· Phase 3· Source

• Active, not recruiting

  A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT06425991· Phase 1· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· Source

• Recruiting

  A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

  NCT05980806· Phase 2· Source

• Active, not recruiting

  A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

  NCT06208150· Phase 3· Source

• Recruiting

  A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

  NCT06150157· Phase 1· Source

• Active, not recruiting

  Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

  NCT06073821· Phase 3· Source

• Recruiting

  A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  NCT05442567· Phase 3· Source

• Recruiting

  Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease

  NCT05599347· Phase 2· Source

• Recruiting

  POST URS Chemotherapy Instillation

  NCT06167057· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Source

• Active, not recruiting

  A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05572515· Phase 3· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Source

• Active, not recruiting

  A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

  NCT05455320· Phase 3· Source

• Recruiting

  Met Non Small Cell Cancer Registry (MOMENT)

  NCT05376891· Source

• Active, not recruiting

  A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT05424822· Phase 1· Source

• Active, not recruiting

  Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

  NCT05316155· Phase 1/2· Source

• Recruiting

  A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

  NCT04779320· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

  NCT05050136· Phase 2· Source

• Active, not recruiting

  A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

  NCT04929210· Phase 4· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Source

• Recruiting

  A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

  NCT04811560· Phase 1/2· Source

• Active, not recruiting

  Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

  NCT04562389· Phase 3· Source

• Recruiting

  A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT04634552· Phase 2· Source

• Active, not recruiting

  RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

  NCT04597125· Phase 4· Source

• Active, not recruiting

  Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04384484· Phase 3· Source

• Active, not recruiting

  Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  NCT04273945· Phase 3· Source

• Active, not recruiting

  A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  NCT03462719· Phase 3· Source

• Active, not recruiting

  Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

  NCT03301506· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma4 recruiting
• Crohn's disease3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Acute myeloid leukaemia2 recruiting
• Bladder cancer2 recruiting
• Childhood cancers2 recruiting
• Lupus (SLE)2 recruiting
• Ulcerative colitis2 recruiting
• Amyloidosis1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Coronary artery disease1 recruiting
• Endometriosis1 recruiting
• Hodgkin lymphoma1 recruiting
• Macular degeneration1 recruiting
• Myelodysplastic syndromes1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

  NCT06522035· Phase 1· Source

• Recruiting

  Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

  NCT06093672· Phase 3· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Source

• Completed

  Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

  NCT05525520· Phase 2· Source

• Completed

  Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

  NCT05536297· Phase 3· Source

• Completed

  A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

  NCT04919512· Phase 2· Source

• Completed

  Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

  NCT05010577· Phase 1/2· Source

• Completed

  Lung EpiCheck Biomarkers Development Study

  NCT06245876· Source

• Completed

  Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer

  NCT04543903· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Source

• Completed

  A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

  NCT04779307· Phase 3· Source

• Completed

  Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

  NCT04936308· Phase 3· Source

• Completed

  A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT04673357· Phase 3· Source

• Completed

  A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT04630028· Phase 3· Source

• Completed

  A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT04540796· Phase 1· Source

• Terminated

  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

  NCT04365868· Phase 2/3· Source

• Completed

  Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

  NCT03677154· Phase 1/2· Source

• Completed

  Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

  NCT03740165· Phase 3· Source

• Completed

  A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  NCT03652064· Phase 3· Source

• Completed

  Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  NCT03196427· Phase 2· Source

• Completed

  A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

  NCT03573310· Phase 1· Source

• Completed

  A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

  NCT03412565· Phase 2· Source

• Completed

  A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

  NCT03301220· Phase 3· Source

• Completed

  A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03277105· Phase 3· Source

Trial sites

• Carmel Medical Center69 trials
• Carmel Medical Center (Site 1007)1 trial
• Carmel Medical Center (Site 704)1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Cystic fibrosis15 works · 1 trial